Capitalization 30.63B 4.21B P/E ratio 2024 *
66.6x
P/E ratio 2025 * 50.2x
Enterprise value 25.55B 3.51B EV / Sales 2024 *
7.63x
EV / Sales 2025 * 5.99x
Free-Float
21.53%
Yield 2024 *
0.11%
Yield 2025 * 0.29%
More valuation ratios * Estimated data
Dynamic Chart
1 day-5.83%
1 week-6.85%
Current month-9.58%
1 month-17.50%
3 months+5.15%
6 months+27.57%
Current year+19.91%
More quotes
1 week
27.68
Extreme 27.68
30.09
1 month
27.68
Extreme 27.68
33.78
Current year
18.59
Extreme 18.59
34.07
1 year
18.59
Extreme 18.59
34.07
3 years
12.93
Extreme 12.93
34.07
5 years
12.93
Extreme 12.93
34.07
10 years
9.43
Extreme 9.43
39.50
More quotes
Manager TitleAgeSince
Chief Executive Officer 61 06-12-31
Director of Finance/CFO 49 16-10-20
Director/Board Member 54 06-12-31
Director TitleAgeSince
Chairman 56 06-12-31
Director/Board Member 54 06-12-31
Chief Executive Officer 61 06-12-31
More insiders

Other Pharmaceuticals

Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-5.83%-6.85%+25.90%+30.76% 4.47B
+2.09%-6.22%+92.24%+261.67% 780B
+1.46%-4.92%+67.69%+223.10% 588B
-1.31%+0.68%-11.13%-11.50% 371B
-0.57%-0.57%+14.65%+60.85% 318B
-0.11%+2.41%+21.03%+46.62% 307B
-2.43%+5.56%-0.07%-21.31% 254B
-0.57%+0.74%+13.08%+43.75% 245B
-0.16%-2.75%+5.93%+13.73% 219B
-0.28%+0.18%+41.77%+34.73% 180B
Average -0.79%-0.87%+27.11%+68.24% 326.71B
Weighted average by Cap. +0.26%-2.16%+40.05%+116.10%
See all sector performances
Ratios2024 *2025 *
Net sales 4.02B 552M 5.11B 703M
Net income 466M 64.03M 617M 84.85M
Net Debt - -
More financial data * Estimated data
Logo Haisco Pharmaceutical Group Co., Ltd.
Haisco Pharmaceutical Group Co.,Ltd., formerly Xizang Haisco Pharmaceutical Group Co., Ltd., is a China-based company principally engaged in the research, development, manufacture and sale of new drugs and high-end medical instrument. The Company’s main products are categorized into small volume injections, big volume injections, freeze-dried powder injections and others, which include polyene phosphatidylcholine injections, lipid solubility vitamins injection series, doradiazine methanesulfonate injections, nalmefene hydrochloride injections, fluprofen tromethamine tablets and cefoperazone sodium tazobactam sodium for injections, among others. The Company distributes its products in domestic market.
Employees
5,448
Calendar
More about the company
Date Price Change Volume
24-07-22 27.76 ¥ -5.83% 3 731 600
24-07-22 29.48 ¥ +0.92% 3,171,867
24-07-19 29.21 ¥ -1.42% 2,721,701
24-07-18 29.63 ¥ -0.24% 2,083,600
24-07-17 29.70 ¥ -0.83% 2,910,329

End-of-day quote Shenzhen S.E., July 22, 2024

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
27.76CNY
Average target price
36.19CNY
Spread / Average Target
+30.37%
Consensus
  1. Stock Market
  2. Equities
  3. 002653 Stock